Literature DB >> 14975768

Bcl-2 and Bcl-xL are important for the induction of paclitaxel resistance in human hepatocellular carcinoma cells.

Eunyoung Chun1, Ki-Young Lee.   

Abstract

In this study we have investigated the mechanism underlying resistance to the chemotherapeutic drug paclitaxel in tumors of hepatocellular carcinoma (HCC) patients. Treatment with paclitaxel led to potent inhibition of growth of Hep3B hepatoma cells, but did not affect the growth properties of SNU-368 and SNU-398 cell lines that were established from primary HCC tumors. The growth inhibitory effect induced by paclitaxel correlated with levels of intracellular p21 and resulted in cell cycle arrest at the G2/M phase. However, paclitaxel treatment did not alter intracellular p53 levels. Instead, SNU-398 cells express high levels of the anti-apoptotic Bcl-2 and Bcl-x(L) proteins and the level of Bcl-x(L) could be further induced upon paclitaxel treatment. In contrast, Hep3B cells express pro-apoptotic members of the Bcl family and fail to induce Bcl-x(L) upon paclitaxel treatment. Therefore, these results strongly suggest that Bcl-2 and Bcl-x(L) play an important role in mediating resistance to paclitaxel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14975768     DOI: 10.1016/j.bbrc.2004.01.118

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

Review 1.  Chemosensitization of tumors by resveratrol.

Authors:  Subash C Gupta; Ramaswamy Kannappan; Simone Reuter; Ji Hye Kim; Bharat B Aggarwal
Journal:  Ann N Y Acad Sci       Date:  2011-01       Impact factor: 5.691

2.  In vitro and in vivo conditional sensitization of hepatocellular carcinoma cells to TNF-induced apoptosis by taxol.

Authors:  V G Minero; D De Stefanis; P Costelli; F M Baccino; G Bonelli
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

3.  Silencing Notch-1 induces apoptosis and increases the chemosensitivity of prostate cancer cells to docetaxel through Bcl-2 and Bax.

Authors:  Qi-Fa Ye; Yi-Chuan Zhang; Xiao-Qing Peng; Zhi Long; Ying-Zi Ming; Le-Ye He
Journal:  Oncol Lett       Date:  2012-01-17       Impact factor: 2.967

4.  Proteome analysis of differential protein expression in cervical cancer cells after paclitaxel treatment.

Authors:  Eun-Kyoung Yim; Jun-Sang Bae; Seung-Bak Lee; Keun-Ho Lee; Chan-Joo Kim; Sung-Eun Namkoong; Soo-Jong Um; Jong-Sup Park
Journal:  Cancer Res Treat       Date:  2004-12-31       Impact factor: 4.679

5.  Systematic expression analysis of genes related to multidrug-resistance in isogenic docetaxel- and adriamycin-resistant breast cancer cell lines.

Authors:  Wen-Jing Li; Shan-Liang Zhong; Yuan-Jian Wu; Wei-Dong Xu; Jin-Jin Xu; Jin-Hai Tang; Jian-Hua Zhao
Journal:  Mol Biol Rep       Date:  2013-11       Impact factor: 2.316

6.  TGF-β induced chemoresistance in liver cancer is modulated by xenobiotic nuclear receptor PXR.

Authors:  Ella Bhagyaraj; Nancy Ahuja; Sumit Kumar; Drishti Tiwari; Shalini Gupta; Ravikanth Nanduri; Pawan Gupta
Journal:  Cell Cycle       Date:  2019-11-18       Impact factor: 4.534

7.  TIP30 regulates apoptosis-related genes in its apoptotic signal transduction pathway.

Authors:  Mei Shi; Xia Zhang; Ping Wang; Hong-Wei Zhang; Bai-He Zhang; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2005-01-14       Impact factor: 5.742

8.  Biology of SNU cell lines.

Authors:  Ja-Lok Ku; Jae-Gahb Park
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

9.  Nucleolin stabilizes Bcl-X L messenger RNA in response to UVA irradiation.

Authors:  Jack Zhang; George Tsaprailis; G Tim Bowden
Journal:  Cancer Res       Date:  2008-02-15       Impact factor: 12.701

10.  Bcl-2-enhanced efficacy of microtubule-targeting chemotherapy through Bim overexpression: implications for cancer treatment.

Authors:  Amandine Savry; Manon Carre; Raphael Berges; Amandine Rovini; Isabelle Pobel; Christine Chacon; Diane Braguer; Véronique Bourgarel-Rey
Journal:  Neoplasia       Date:  2013-01       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.